HOME >> BIOLOGY >> NEWS
Weizmann Insitute scientists show how proteins beat the evolutionary stakes

Evolution is something of a gamble: in order to stay a step ahead of a shifting environment, organisms must change or risk extinction. Yet the instrument of this change, mutation, carries a serious threat: mutations are hundreds of times more likely to be harmful to the organism than advantageous. Now, in a paper published online Nov. 28 in Nature Genetics, a team of scientists at the Weizmann Institute of Science has shown one way that evolving organisms may be hedging their bets.

Dr. Dan Tawfik, who headed the team from the Biological Chemistry Department, believes that proteins with so-called promiscuous or moonlighting activities can provide nature with ready-made starting points for the evolution of new functions. Proteins that have evolved to perform a given function often have the ability to take on other, often completely unrelated tasks as well. For example, one of the enzymes studied by the group, PON1, is known to remove cholesterol from artery walls, as well as to break up a certain chemicals used as pesticides.

Yet its main function is to act as a catalyst for the removal of a class of compounds called lactones that have no connection at all to the other two.

To investigate what kind of evolutionary advantage promiscuity offers, the team created a speeded-up version of evolution in the lab. Mutations were introduced into the genes coding for various proteins in a completely random manner. Evolutionary pressure was then simulated by selecting those mutants with higher levels of activity in one of the promiscuous traits.

After several rounds of mutation and selection, the scientists looked at their enzymes to see what had changed. As expected, they had managed to increase the activity they were selecting for by as much as a hundredfold and more. But how did increasing one skill affect the others?

Interestingly, the levels of the other promiscuous activities also underwent drastic changes. In most cases, the lev
'"/>

Contact: Yivsam Azgad
yivsam.azgad@weizmann.ac.il
American Committee for the Weizmann Institute of Science
21-Dec-2004


Page: 1 2 3

Related biology news :

1. Weizmann Institute scientists discover a control mechanism for metastasis
2. Weizmann scientists discover a new line of communication between nervous system cells
3. Weizmann Institute scientists develop a general control switch for protein activity
4. Weizmann Institute scientists discover a key player in embryonic muscle development
5. Weizmann Institute scientists discover genes that can slow cell division and may fight cancer
6. Weizmann Women & Science Award presented to Dr. Mary-Claire King
7. Mary-Claire King to receive the 2006 Weizmann Women & Science Award
8. Weizmann Institute scientists discover a molecular security mechanism for keeping mutations in check
9. Weizmann Institute suggests that immune cells help to maintain cognition and brain cell renewal
10. Weizmann Institute scientists discover how substitutions are made for injured genes
11. Technology award presented to Weizmann Institute scientist

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/3/2019)... ... 02, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... approved clinical trial for stem cell treatment of knee osteoarthritis . The successful enrollment ... a subsidiary of VetStem Biopharma. , PSC CEO, Michael Dale, stated, “We are proud ...
(Date:9/30/2019)... ... September 30, 2019 , ... RoosterBio ... stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent approval ... formats (patent number AU 2015259373). This new patent adds intellectual property (IP) ...
(Date:9/25/2019)... ... September 25, 2019 , ... Deep Science Ventures (DSV), a ... world’s largest independent funder of cancer research. , Deep Science Ventures was founded to ... view of the opportunity from the start, both at the industry and biological level. ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... (PRWEB) , ... October 02, 2019 , ... ... new life sciences leadership firm that is enabling clinical program outsourcing success by ... Founded by award-winning pharma and biotech veteran executive Brenda Reese, phaseUP™ brings clients ...
(Date:10/3/2019)... ... , ... Yesterday, at the 2019 meeting of Outsourcing in Clinical Trials New ... M.D., Ph.D., discussed important design factors that currently limit the success of early stage ... of clinical trials, in his talk Dr. Sherley focused on the highly ...
(Date:9/24/2019)... and WALTHAM, Mass. (PRWEB) , ... ... ... the leading global provider of advanced delivery technologies, development, and manufacturing solutions ... Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of ...
(Date:9/22/2019)... BEAVERTON, Ore. (PRWEB) , ... September 20, 2019 ... ... the commercial launch of Brain-Derived Neurotrophic Factor (BDNF) testing in serum . ... peripheral nervous systems. BDNF stimulates the growth and differentiation of new neurons in ...
Breaking Biology Technology:
Cached News: